Oral News and Research

RSS

Several medications can help people with alcohol use disorders quit drinking

Several medications can help people with alcohol use disorders maintain abstinence or reduce drinking, according to research from the University of North Carolina at Chapel Hill.

14 May 2014

Ajinomoto announces Phase 2a results of oral alpha 4 integrin antagonist AJM300 in ulcerative colitis patients

Ajinomoto Pharmaceuticals Co., Ltd. (President, Takashi Nagamachi; Headquarters, Tokyo, Japan) announced on May 13 that the Phase 2a results of an oral alpha 4 integrin antagonist, AJM300, in patients with ulcerative colitis were presented in the Joint Presidential Plenary Session at Digestive Disease Week (DDW) 2014 held May 3 - 6 in Chicago, IL, USA.

13 May 2014

New breakthrough offers easier way of detecting pathogenic bacteria outside clinical setting

The breakthrough, published in the journal Nature Materials, could offer an easier way of detecting pathogenic bacteria outside of a clinical setting and could be particularly important for the developing world, where access to more sophisticated laboratory techniques is often limited.

13 May 2014

Spring Bank announces 3 presentations on SB 9200 at 27th ICAR

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B (HBV) and Hepatitis C (HCV) infections, at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the Raleigh Convention Center in Raleigh, NC.

12 May 2014

Federal judges hear 'origination clause' challenge to health law

The case, brought by the Pacific Legal Foundation in Sacramento, Calif., argues the law's insurance mandate is unconstitutional because the Constitution's origination clause requires all revenue-raising measures to originate in the House of Representatives and this legislation began in the Senate.

12 May 2014

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma, Inc. today reported operating and financial results for the first quarter ended March 31, 2014.

9 May 2014

Research on laser assisted drug delivery selected for April 2014 issue of LSM

Research conducted by Lindsay R. Sklar, M.D., Christopher T. Burnett, M.D., F.A.A.D., Jill S. Waibel, M.D., F.A.A.D., Ronald L. Moy, M.D., F.A.A.D., and David M. Ozog, M.D., F.A.A.D., was selected as Editor’s Choice for the April 2014 issue of Lasers in Surgery and Medicine.

9 May 2014

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

AbbVie submitted marketing authorization applications (MAAs) to the European Medicines Agency seeking approval for the company’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

9 May 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

9 May 2014

Veracyte's revenue increases 71% to $7.5 million in Q1 2014

Veracyte, Inc. today reported financial results for the first quarter ended March 31, 2014, and provided an update on recent business progress. For the first quarter of 2014, revenue was $7.5 million, an increase of 71%, compared to $4.4 million for the first quarter of 2013.

9 May 2014

New Aspen Dental office to open in Murfreesboro, TN on June 5

A new Aspen Dental office is opening in Murfreesboro, TN on Thursday, June 5. Located at 2711 Medical Center Parkway, the conveniently located practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.

9 May 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

Freeman Health System wins 2014 Truven Health Advantage Award for Overall Performance

Mike Boswood, president and CEO of Truven Health Analytics presented the 2014 Truven Health Advantage Award for Overall Performance to Freeman Health System, a not-for-profit, three-hospital system in Joplin, Missouri.

8 May 2014

New Aspen Dental office to open in St. Augustine, FL

A new Aspen Dental office is opening in St. Augustine, FL on Thursday, June 5. Located at 1747 US Highway 1 South, the conveniently located practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.

8 May 2014

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

State highlights: SEIU, hospital strike deal in Calif.; N.Y. Medicaid audit; dental therapists

A selection of health policy stories from California, New York, Connecticut, Georgia, Indiana and North Carolina.

8 May 2014

Ambrisentan cleared for use with phenprocoumon

Starting treatment with ambrisentan does not necessitate adjusting the dose of the oral anticoagulant phenprocoumon in patients with pulmonary hypertension who require both medications, report researchers.

7 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

First Edition: May 7, 2014

Today's headlines include a story noting that insurers say about 80 percent of new enrollees have paid their first premiums for new insurance coverage under the health law.

7 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Oral News and Research

Several medications can help people with alcohol use disorders quit drinking

Ajinomoto announces Phase 2a results of oral alpha 4 integrin antagonist AJM300 in ulcerative colitis patients

New breakthrough offers easier way of detecting pathogenic bacteria outside clinical setting

Spring Bank announces 3 presentations on SB 9200 at 27th ICAR

Federal judges hear 'origination clause' challenge to health law

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Research on laser assisted drug delivery selected for April 2014 issue of LSM

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Veracyte's revenue increases 71% to $7.5 million in Q1 2014

New Aspen Dental office to open in Murfreesboro, TN on June 5

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Freeman Health System wins 2014 Truven Health Advantage Award for Overall Performance

New Aspen Dental office to open in St. Augustine, FL

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

State highlights: SEIU, hospital strike deal in Calif.; N.Y. Medicaid audit; dental therapists

Ambrisentan cleared for use with phenprocoumon

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

First Edition: May 7, 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News